Thank you @ASCO for selecting our work in #FLC and helping highlight the importance of talking about #rare cancers. Awareness leads to research, and research leads to hope @MarkYarchoan@FibroFoundation
🚨 Just published! 🚨 Thrilled to share our new study:
“Propensity score–weighted analysis of neoadjuvant therapy vs. upfront surgical resection in biliary tract cancers” 📎 Read it here: https://t.co/jtkFKjLvtL
#Oncology#SurgOnc#BiliaryCancer#NeoadjuvantTherapy
🚨 New manuscript led by @marinabaretti, @curecc
Using #CODEX multiplexed imaging:
🧬 #CCA is rich in CAFs,TAMs,MDSCs, scarce CD8 T cells (~1.8% of all cells)
🧬 FGFR2 fusions → ⬆️ CD11b+/CD15+ granulocytes
🧬 IDH1 mutations → trend ⬆️M2-like mac
🔗https://t.co/8k55IvNeG8
In light of the negative #IMbrave050 study (no benefit w/ adj atezo+bev), a timely study by @mnakazawa7 supporting neoadj ICI (NI)
⏩https://t.co/7CZxOpXyVC
⏩NI may allow pts outside of traditional resection criteria to achieve long term survival
⏩Prospective trials warranted!
We often pursue ~5 years of surveillance for liver cancer. Longer surveillance may be warranted for #fibrolamellar#HCC. @marinabaretti@elsa_hallab
⏩A Recurrence of Fibrolamellar HCC After 18 Years:
https://t.co/NNESLTg82w